Status:
COMPLETED
DNA Chip Based Prognosis of Lung Cancer
Lead Sponsor:
Medical Prognosis Institute A/S
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lun...
Eligibility Criteria
Inclusion
- A histological diagnosis of primary NSCLC stage Ia
- Surgical removal of the tumor
- Age between 18 and 75 years
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
- Adjuvant treatment with chemotherapy.
- Prior history of cancer in the past 5 years or breast cancer at any time.
- Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT00973427
Start Date
June 1 2008
End Date
September 1 2014
Last Update
September 23 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
3
Aarhus University Hospital
Aarhus, Denmark, 8200
4
University of Copenhagen
Copenhagen, Denmark, 2100